MarginsXMarginsX
Home › Markets › Health Care › XTLB

XTL Biopharmaceuticals Ltd. (XTLB)

XTLB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.54
-3.75% on the day
Market cap
$3.8M
Nano cap
Revenue · 2024
$451K
No prior year to compare
Net income · 2024
-$1.0M
-227.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1023549/000121390025037590/0001213900-25-037590-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerXTLB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001023549
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2024

LineValue
Revenue$451K
Net income-$1.0M
Operating income-$2.2M
Net margin-227.7%
Operating margin-481.6%
Revenue growthNo prior-year revenue to compare
Cash$371K
Total assets$8.6M
P/E (computed)Net income was not positive
P/S (computed)8.4×

Warning signs

Cash runway
0.9 months
$76K cash at December 31, 2025
Share count, 1 year
+329.4%
2024-12-31 to 2025-12-31 · +594.6% over 3 years
Going-concern doubt
Yes
20-F filed June 30, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1: GENERAL (Cont.) These factors, individually and in the aggregate, raise substantial doubt about the Company's ability to continue as a going concern."
20-F 2026-06-30
Cash and burn$76K cash; operating cash flow -$256K a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-4 on 2026-03-25Source 2026-03-25
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBarzily&Co Certified Public Accountants, Jerusalem, IsraelPCAOB Form AP 2026-07-02
Late filings, 12 months1 NT noticeNT 20-F 2026-04-30
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$7.0M-$1.0M$76KNo debt tagsNeeds four quarters20-F 2026-06-30
FY 2024
2024-12-31
$451K-$1.0M-$1.6M$371K$138K$451K20-F 2025-04-30
FY 2023
2023-12-31
Not filed-$1.8M-$707K$1.4MNo debt tagsNeeds four quarters20-F 2025-04-30
FY 2022
2022-12-31
Not filed-$1.3M-$901K$2.1MNo debt tagsNeeds four quarters20-F 2025-04-30
FY 2021
2021-12-31
Not filed$435K-$1.0M$3.0MNo debt tagsNeeds four quarters20-F 2023-03-22
FY 2020
2020-12-31
Not filed-$3.0M-$850K$3.6MNo debt tagsNeeds four quarters20-F 2023-03-22
FY 2019
2019-12-31
Not filed-$763K-$908K$4.5MNo debt tagsNeeds four quarters20-F 2022-03-30
FY 2018
2018-12-31
Not filed$3.6M-$816K$3.3MNo debt tagsNeeds four quarters20-F/A 2021-05-19

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B32021-06-09
Latest annual report
ANNUAL REPORT
20-F2026-06-30
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-10-14

Source: SEC EDGAR submissions feed, 546 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.2%
1 month-19.2%
3 months-42.9%
Year to date-31.0%
1 year-57.4%
From 52-week high-62.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AZTRAzitra Inc$0.6270+3.06%$3.8M
GELSGelteq Limited$0.3589-5.63%$3.8M
IMNNImunon Inc.$0.5940-5.56%$3.9M
TRAWTraws Pharma Inc.$0.2600+3.59%$4.0M
XBIOXenetic Biosciences Inc.$1.49-10.24%$3.5M
SILOSilo Pharma Inc.$1.57-14.40%$3.4M
BGMSBio Green Med Solution Inc.$0.6502+1.55%$4.3M
KPRXKiora Pharmaceuticals Inc.$0.9820-20.16%$4.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier